secwatch / observer
8-K filed June 11, 2026, 4:28 PM ET ticker JBIO CIK 0001798749
other confidence high sentiment neutral materiality 0.20

Jade Biosciences stockholder meeting approves jury trial waiver and adopts amended bylaws

Jade Biosciences, Inc.

item 3.03item 5.03item 5.07item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Jade Biosciences, Inc.: Amendment to Articles of Incorporation to waive jury trials in certain circumstances, effective June 10, 2026 (effective 2026-06-10).

Change
charter amendment
Effective
2026-06-10
Exact text from the filing
At the 2026 Annual Meeting, as described below under Item 5.07, the stockholders of the Company approved an amendment to the Company’s Articles of Incorporation to waive jury trials in certain circumstances (the “Amendment”). The Amendment became effective upon the Company’s filing of Amended and Restated Articles of Incorporation, including the Amendment as a new Article X, with the Nevada Secretary of State on June 10, 2026
View on SEC.gov
Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Jade Biosciences, Inc.: Amended and Restated Bylaws to make technical, modernizing and clarifying changes consistent with the Nevada Revised Statutes, effective June 9, 2026 (effective 2026-06-09).

Change
bylaw amendment
Effective
2026-06-09
Exact text from the filing
On June 8, 2026, the Board of Directors (the “Board”) of the Company approved and adopted amended and restated bylaws (the “Amended and Restated Bylaws”), which became effective on June 9, 2026, to make certain technical, modernizing and clarifying changes consistent with the current Nevada Revised Statutes (the “NRS”).
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Jade Biosciences, Inc. shareholders approved Ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-09 meeting.

Proposal
auditor ratification
Outcome
passed
Meeting
2026-06-09
Exact text from the filing
Proposal to ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The appointment was ratified by the votes indicated: For Against Abstain Broker Non-Votes 46,003,217 3,322 137 0
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Jade Biosciences, Inc. shareholders approved Election of two Class II Directors to serve until the 2029 Annual Meeting of Stockholders at the 2026-06-09 meeting.

Proposal
director election
Outcome
passed
Meeting
2026-06-09
Exact text from the filing
The following two Class II Directors were elected by the votes indicated: For Withheld Broker Non-Votes Christopher Cain, Ph.D. 34,373,784 8,041,605 3,591,287 Tom Frohlich 42,399,190 16,199 3,591,287
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Jade Biosciences, Inc. shareholders approved Approve an amendment to the Company’s Articles of Incorporation to waive jury trials in certain circumstances at the 2026-06-09 meeting.

Proposal
charter amendment
Outcome
passed
Meeting
2026-06-09
Exact text from the filing
Proposal to approve an amendment to the Company’s Articles of Incorporation to waive jury trials in certain circumstances. The proposal was approved by the votes indicated: For Against Abstain Broker Non-Votes 39,933,495 2,481,659 235 3,591,287
View on SEC.gov

255 governance changes filed in the last 30 days. Browse all governance changes →

Jade Biosciences, Inc. filing history →

Source: SEC EDGAR
accession 0001193125-26-267640
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.